DK0889969T3 - Rekombinante adenovirale til genterapi af humane tumorer - Google Patents

Rekombinante adenovirale til genterapi af humane tumorer

Info

Publication number
DK0889969T3
DK0889969T3 DK97914375T DK97914375T DK0889969T3 DK 0889969 T3 DK0889969 T3 DK 0889969T3 DK 97914375 T DK97914375 T DK 97914375T DK 97914375 T DK97914375 T DK 97914375T DK 0889969 T3 DK0889969 T3 DK 0889969T3
Authority
DK
Denmark
Prior art keywords
gene therapy
disclosed
human tumors
recombinant adenoviral
treating
Prior art date
Application number
DK97914375T
Other languages
English (en)
Inventor
Michel Perricaudet
Falleur Boon
Marie-Therese Duffour
Hedi Haddada
Christophe Lurquin
Catherine Uyttenhoveghesquiere
Guy Warnier
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centelion filed Critical Centelion
Application granted granted Critical
Publication of DK0889969T3 publication Critical patent/DK0889969T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK97914375T 1996-03-14 1997-03-12 Rekombinante adenovirale til genterapi af humane tumorer DK0889969T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9603207A FR2746110B1 (fr) 1996-03-14 1996-03-14 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants

Publications (1)

Publication Number Publication Date
DK0889969T3 true DK0889969T3 (da) 2006-03-27

Family

ID=9490181

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97914375T DK0889969T3 (da) 1996-03-14 1997-03-12 Rekombinante adenovirale til genterapi af humane tumorer

Country Status (19)

Country Link
US (1) US20030082150A1 (da)
EP (1) EP0889969B1 (da)
JP (1) JP2000507229A (da)
KR (1) KR19990087718A (da)
CN (1) CN1218512A (da)
AT (1) ATE309382T1 (da)
AU (1) AU732288B2 (da)
BR (1) BR9707994A (da)
CA (1) CA2248612A1 (da)
CZ (1) CZ295967B6 (da)
DE (1) DE69734574T2 (da)
DK (1) DK0889969T3 (da)
ES (1) ES2252779T3 (da)
FR (1) FR2746110B1 (da)
HU (1) HUP9902150A3 (da)
IL (1) IL126152A0 (da)
NO (1) NO984052L (da)
SK (1) SK124698A3 (da)
WO (1) WO1997034009A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4668797A (en) * 1996-10-07 1998-05-05 Ludwig Institute For Cancer Research Replication-defective adenoviruses for cancer immunotherapy
CA2388337C (en) 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US7306792B2 (en) * 2001-03-27 2007-12-11 New York University Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
ES2290449T3 (es) 2002-04-09 2008-02-16 Sanofi Pasteur Limited Acido nucleico de cea modificado y vectores de expresion.
JP2005523942A (ja) * 2002-04-30 2005-08-11 アヴィオル セラピューティクス インコーポレイテッド 免疫療法のためのアデノウイルスベクター
CN1327000C (zh) * 2002-09-06 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 靶向黑色素瘤的可复制性腺病毒穿梭载体及腺病毒
EP1556082A1 (en) * 2002-10-22 2005-07-27 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
SK282843B6 (sk) * 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom

Also Published As

Publication number Publication date
IL126152A0 (en) 1999-05-09
KR19990087718A (ko) 1999-12-27
DE69734574T2 (de) 2006-07-13
US20030082150A1 (en) 2003-05-01
SK124698A3 (en) 1999-05-07
ATE309382T1 (de) 2005-11-15
CN1218512A (zh) 1999-06-02
AU2164197A (en) 1997-10-01
EP0889969B1 (fr) 2005-11-09
FR2746110A1 (fr) 1997-09-19
NO984052D0 (no) 1998-09-03
DE69734574D1 (de) 2005-12-15
HUP9902150A2 (hu) 1999-11-29
WO1997034009A1 (fr) 1997-09-18
CA2248612A1 (fr) 1997-09-18
ES2252779T3 (es) 2006-05-16
BR9707994A (pt) 1999-07-27
CZ291598A3 (cs) 1998-12-16
JP2000507229A (ja) 2000-06-13
NO984052L (no) 1998-09-03
EP0889969A1 (fr) 1999-01-13
AU732288B2 (en) 2001-04-12
CZ295967B6 (cs) 2005-12-14
FR2746110B1 (fr) 1998-04-17
HUP9902150A3 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
DE69637642D1 (de) Und kombinierte zusammensetzungen und deren verwendung
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
ATE375362T1 (de) Von cyclophilin b abstammende tumorantigen- peptide
DE69731611D1 (de) Eine Zusammensetzung enthaltend eine Detergenz und einen ein Tumorsuppressorgen kodierenden, adenoviralen Vektor
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
NO953684L (no) Fremgangsmåte for fremstilling av kreftvaksiner
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
ATE295853T1 (de) Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen
AR004341A1 (es) Vacunas contra tumores y procedimiento para su produccion.
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
DE60238044D1 (de) Tumortherapie mit vektoren auf sindbis virus-basis
AR029624A1 (es) Anticuerpos o fragmentos de anticuerpos anti-idiotipicos recombinantes y composicion farmaceutica que los contiene
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
AR019844A1 (es) Polipeptidos composicion farmaceutica, procedimiento para preparar dicha composicion metodo para tratar y prevenir el cancer y metodo para inhibir elcrecimiento de celulas tumorales
DK1007717T3 (da) Metoder og sammensætninger til cancerterapi under anvendelse af gener, der koder for interferon-beta
DK0938329T3 (da) Immunogen TLP sammensætning
UY26170A1 (es) Antigeno (c42) asociados a tumores
ATE308565T1 (de) Immunogene alk (anaplastic lymphoma kinase) peptide
ATE291620T1 (de) Mammakarzinom-assoziiertes gen
DK0788355T3 (da) Anvendelse af intravenøst indgiveligt jern til behandling af tumorsygdomme og/eller infektionssygdomme